Spyre Therapeutics is a clinical-stage biotechnology company that aims to create next-generation inflammatory bowel disease (IBD) products by combining best-in-class antibody engineering, rational ...

Aeglea BioTherapeutics is rebranding, unveiling a new name and a host of leadership changes. The company announced Monday that it will go by its new name, Spyre Therapeutics, and has a host of ...

Spyre Therapeutics Announces First Participants Dosed in Phase 1 Trial of SPY001, its Novel Half-life Extended anti-α4β7 Antibody, for the Treatment of Inflammatory Bowel Disease ...

Spyre, the second spinout from Paragon Therapeutics, is advancing a pipeline of product candidates, led by SPY001 and SPY002, that are potentially best-in-class antibodies targeting a4b7 and TL1A ...

Spyre Therapeutics Corp has a consensus price target of $567.61 based on the ratings of 38 analysts. The high is $1350 issued by HSBC on May 10, 2024<.

Julian Harrison has given his Buy rating due to a combination of factors surrounding the promising developments at Spyre Therapeutics. The company’s strategic decision to expand its TL1A program ...

WALTHAM, Mass., July 03, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company utilizing best-in-class ...